Day: December 8, 2023

Company announcement no 8 2023  Danske Bank A/SHolmens Kanal 2 – 12DK – 1092 København KTel. +45 45 14 00 00 8 December 2023Danske Bank A/S revises 2023 net profit outlook upwards Now expects a net profit in the range of DKK 20.5-21.5 billionThe outlook for 2023 is revised upwards to a net profit in the range of DKK 20.5-21.5 billion. At the release of our interim report for the first nine months on 27 October this year, we guided for a full-year 2023 net profit in the range of DKK 19.5-20.5 billion. The profit upgrade follows our continually strong credit quality and expectedly negligible impairments for the fourth quarter of 2023. As such, we now expect full-year loan impairment charges to be around DKK 0.3 billion as reported in the interim report for the first nine months of the year. “The macroeconomic conditions have...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES Oslo, 8 December 2023 – Reference is made to (i) the announcement made by BW Sirocco Holdings AS (the “Offeror) on 9 November 2023 regarding a recommended voluntary offer to acquire all the issued and outstanding shares (the “Shares“) in BW Ideol AS (“BW Ideol” or the “Company“), not already held by the Initiating Shareholders (as defined in the Offer Document), at an offer price of NOK 12 per Share (the “Offer Price“), to be settled in cash or shares in the Offeror...

To Nasdaq Copenhagen A/S         Replacement in bonds for new lending On January 3, 2024, the following replacements of bonds for new loan offers will take place in Totalkredit A/S and Nykredit Realkredit A/S.Loan Type Current Bond New BondCibor3 (SDO)ISIN DK0009543811 ISIN DK0009545352Interest rate spread 0.10% Interest rate spread 0.15%Maturity date 01-10-2025 Maturity date 01-10-2026Closing date 31-07-2025 Closing date 31-07-2026Cibor3 (RO)ISIN DK0009541526 ISIN DK0009545436Interest rate spread 0.20% Interest rate spread 0.25%Maturity date 01-04-2025 Maturity date 01-04-2026Closing date 31-01-2025 Closing date 31-01-2026Loan disbursement will occur in the bond specified in the loan offer. The current bonds can still be used for new lending until the closing date, but starting from the change date, the...

To Nasdaq Copenhagen A/S         Replacement in bonds for new lending On January 3, 2024, the following replacements of bonds for new loan offers will take place in Totalkredit A/S and Nykredit Realkredit A/S.Loan Type Current Bond New BondCibor3 (SDO)ISIN DK0009543811 ISIN DK0009545352Interest rate spread 0.10% Interest rate spread 0.15%Maturity date 01-10-2025 Maturity date 01-10-2026Closing date 31-07-2025 Closing date 31-07-2026Cibor3 (RO)ISIN DK0009541526 ISIN DK0009545436Interest rate spread 0.20% Interest rate spread 0.25%Maturity date 01-04-2025 Maturity date 01-04-2026Closing date 31-01-2025 Closing date 31-01-2026Loan disbursement will occur in the bond specified in the loan offer. The current bonds can still be used for new lending until the closing date, but starting from the change date, the...

Sanoma Corporation, Managers’ Transactions, 8 December 2023 at 11:15 EET CORRECTION: Sanoma Corporation – Managers’ Transactions Sanoma Corporation corrects its stock exchange release about the Managers’ Transactions published earlier today. In the earlier release the name of the legal person subject to the notification requirement was Sanoma Oyj while the correct legal person is Holding Manutas Oy. The corrected stock exchange release is available below. ___________________________________________Person subject to the notification requirementName: Holding Manutas OyPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Anna HerlinPosition: Member of the BoardIssuer: Sanoma OyjLEI: 743700XJC24THUPK0S03Notification type: INITIAL NOTIFICATIONReference number: 45488/4/6____________________________________________Transaction...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeSmart Metering Systems plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Advisor and Joint Broker to Smart Metering Systems plc(d)        Date dealing undertaken: 7th December 2023(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If...

Höegh AutolinersHöegh AutolinersCARGOTEC CORPORATION, PRESS RELEASE, 8 DEC 2023 AT 10 AM EET MacGregor, part of Cargotec, has been selected to supply comprehensive packages of RoRo equipment for an additional four multi-fuel and zero-carbon ready Aurora class Pure Car and Truck Carriers (PCTCs) for Höegh Autoliners. This will extend Höegh Autoliners’ Aurora class newbuilding program to twelve vessels, all of which will be built by China Merchant Heavy Industries (Jiangsu) Co., Ltd.  The significant order is booked into Cargotec’s 2023 fourth quarter order intake and the vessels will be delivered between the second quarter 2026 and the first half of 2027.  The Aurora class will be the future of the PCTC industry with capabilities to transport up to 9,100 cars and by being the world’s largest and most environmentally friendly car...

US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor.Acceptance triggers a first milestone payment. Further milestones are expected upon US and European launches which could now happen in 2Q24 in the US (FDA PDUFA1 action date: June 10, 2024) and 2H24 in Europe. These milestones total approximately 89M€.Launches in the US and Europe will also make GENFIT eligible for royalty payments. Revenues will fund the development of GENFIT’s pipeline, now mainly focused on Acute On-Chronic Liver Failure (ACLF) with 5 differentiated assets.Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 8, 2023 – GENFIT (Nasdaq and...

PRESS RELEASE – INSIDE INFORMATION This is a corrected version of the original PR ” BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease” published on December 6, 2023, 7am CEST where TrialCap Pte. Ltd., as part of the SPRIM Global Investments group (SGI), is named as the lender.    Biosenic signs term sheet with TrialCap Pte. Ltd. for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 8, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell...